Breaking News Instant updates and real-time market news.

SPHS

Sophiris Bio

$3.07

0.5 (19.46%)

09:45
08/29/18
08/29
09:45
08/29/18
09:45

Sophiris Bio price target raised to $10 from $4.30 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised his price target for Sophiris Bio to $10 after the company and investigators found that the death of a patient is unlikely to have been related to either topsalysin or the procedure. Today's information allows focus to return to the underlying investment case on Sophiris, subsequent to the positive Phase 2b data announced on June 25, Pantginis tells investors in a research note. The analyst reiterates a Buy rating on Sophiris Bio.

SPHS Sophiris Bio
$3.07

0.5 (19.46%)

06/25/18
PIPR
06/25/18
NO CHANGE
Target $7
PIPR
Overweight
Piper says Sophiris Bio 'worth sticking with' despite patient death in trial
A patient death after retreatment has "placed a cloud" over Sophiris Bio's topsalysin program despite efficacy data that was "clearly a home run," according to Piper Jaffray analyst Christopher Raymond. He sees a good chance the incident may end up not being categorized as drug-related, noting that topsalysin previously had shown a "pristine safety profile," and Raymond thinks the stock is "worth sticking with" at this point. The analyst, who is reserving judgment until more detail on topsalysin's role in the death is available, thinks there remains a credible path forward even if the death is deemed drug related. He keeps an Overweight rating and $7 price target on Sophiris shares, which fell about 40% to $2.24 today.
06/26/18
PIPR
06/26/18
NO CHANGE
Target $7
PIPR
Overweight
Sophiris Bio 'worth sticking with' after patient death, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond maintained an Overweight rating and $7 price target on Sophiris Bio following disclosure of Phase 2b topsalysin data in localized prostate cancer. In a research note to investors, Raymond contended that while a patient death is "never a great headline," and that death after retreatment has now placed a cloud over the program, he thinks there is a good chance this incident may end up not being categorized as drug-related, and thinks it's worth "sticking with it here." Raymond sees a "credible" path forward with single administration, and urges investors to be patient on the name as clarity on the death and clinical path come more into focus.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $7
PIPR
Overweight
Sophiris Bio topsalycin trial death disclosure imminent, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $7 price target on Sophiris Bio after its "uneventful" Q2 report. The analyst says that while the company did not update on the cause of death of one of its Phase 2b topsalycin trial patients, conversations with the management suggest that the disclosure is "imminent". Raymond adds that with the cause of death being announced, the "cloud" over the program will be lifted, allowing investors to focus on the drug's "impressive efficacy".
08/29/18
PIPR
08/29/18
NO CHANGE
Target $7
PIPR
Overweight
Piper expects shares of Sophiris Bio to open 'sharply higher'
Piper Jaffray analyst Christopher Raymond expects shares of Sophiris Bio to open "sharply higher" on this morning's formal confirmation that topsalysin was not a factor in a patient death seen in the drug's Phase 2b study in patients with localized prostate cancer. In that the death "cast a pall over an otherwise positive data release, we expect the stock to react favorably this morning," Raymond tells investors in a research note. He points out that moving forward, Sophiris has indicated a Phase 3 study confirming the clinical response rate is planned likely next year. The analyst likes the set-up for topsalysin and keeps an Overweight rating on Sophiris Bio with a $7 price target. The stock in premarket trading is up 23%, or 58c, to $3.14.

TODAY'S FREE FLY STORIES

MRK

Merck

$70.79

0.8 (1.14%)

16:32
09/20/18
09/20
16:32
09/20/18
16:32
Hot Stocks
Merck receives positive CHMP opinion for DELSTRIGO and PILFETRO in E.U. »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 23

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

16:30
09/20/18
09/20
16:30
09/20/18
16:30
Options
Preliminary option volume of 24.2M today »

Preliminary option volume…

INDB

Independent Bank

$89.85

0.65 (0.73%)

, BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

16:29
09/20/18
09/20
16:29
09/20/18
16:29
Hot Stocks
Independent Bank to acquire Blue Hills Bancorp »

Independent Bank (INDB),…

INDB

Independent Bank

$89.85

0.65 (0.73%)

BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTV

Veritiv

$44.70

-0.65 (-1.43%)

16:29
09/20/18
09/20
16:29
09/20/18
16:29
Syndicate
Veritiv files to sell 1.5M shares of common stock for holders »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTV

Veritiv

$44.70

-0.65 (-1.43%)

16:29
09/20/18
09/20
16:29
09/20/18
16:29
Syndicate
Veritiv files to sell 1.5M shares of common stock for UWW Holdings, LLC »

Morgan Stanley & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FATE

Fate Therapeutics

$14.02

0.67 (5.02%)

16:26
09/20/18
09/20
16:26
09/20/18
16:26
Syndicate
Fate Therapeutics $100M Spot Secondary; re-offered at $13.50 »

Jefferies, Piper Jaffray…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

TMDI

Titan Medical

$2.22

0.04 (1.83%)

16:25
09/20/18
09/20
16:25
09/20/18
16:25
Conference/Events
Titan Medical to host business news update and outlook conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 27

    Nov

SRE

Sempra Energy

$114.32

0.025 (0.02%)

, ED

Consolidated Edison

$78.43

0.11 (0.14%)

16:22
09/20/18
09/20
16:22
09/20/18
16:22
Hot Stocks
Sempra Energy to sell U.S. solar assets to Consolidated Edison »

Sempra Energy (SRE)…

SRE

Sempra Energy

$114.32

0.025 (0.02%)

ED

Consolidated Edison

$78.43

0.11 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Oct

  • 11

    Nov

GTN

Gray Television

$17.35

0.4 (2.36%)

16:21
09/20/18
09/20
16:21
09/20/18
16:21
Hot Stocks
Gray Television reaches agreement to renew all Gray NBC affiliations »

Gray Television has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AMZN

Amazon.com

$1,944.26

17.99 (0.93%)

, WFC

Wells Fargo

$55.57

0.34 (0.62%)

16:21
09/20/18
09/20
16:21
09/20/18
16:21
General news
Fly Intel: Wall Street's top stories for Thursday »

Stocks opened in positive…

AMZN

Amazon.com

$1,944.26

17.99 (0.93%)

WFC

Wells Fargo

$55.57

0.34 (0.62%)

GE

General Electric

$12.47

-0.39 (-3.03%)

DIS

Disney

$111.62

1.74 (1.58%)

SKYAY

Sky

$0.00

(0.00%)

CMCSA

Comcast

$37.81

0.49 (1.31%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$44.20

-0.05 (-0.11%)

FOXA

21st Century Fox

$44.59

-0.01 (-0.02%)

UAA

Under Armour

$20.01

1.26 (6.72%)

UA

Under Armour

$18.16

0.88 (5.09%)

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

FOLD

Amicus

$12.64

0.84 (7.12%)

SFIX

Stitch Fix

$41.65

-5.56 (-11.78%)

THO

Thor Industries

$91.77

-13.95 (-13.20%)

RHT

Red Hat

$134.06

-9.32 (-6.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 01

    Oct

  • 01

    Oct

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Nov

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

URG

UR-Energy

$0.93

0.0406 (4.58%)

16:21
09/20/18
09/20
16:21
09/20/18
16:21
Syndicate
UR-Energy files to sell common stock and warrants »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URG

UR-Energy

$0.93

0.0406 (4.58%)

16:20
09/20/18
09/20
16:20
09/20/18
16:20
Syndicate
UR-Energy files to sell common stock, warrants, no amount given »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
09/20/18
09/20
16:20
09/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for September 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

16:18
09/20/18
09/20
16:18
09/20/18
16:18
Hot Stocks
Pier 1 Imports CEO says disappointing Q2 reflects 'execution challenges' »

CEO Alasdair James said:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CULP

Culp, Inc.

$24.75

-0.1 (-0.40%)

16:18
09/20/18
09/20
16:18
09/20/18
16:18
Hot Stocks
Culp CEO Saxon to assume additional role of vice chairman »

Culp announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

ED

Consolidated Edison

$78.43

0.11 (0.14%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Hot Stocks
Con Edison to acquire 981 MW of renewable electric production projects »

Consolidated Edison…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

DOV

Dover

$89.36

0.94 (1.06%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Hot Stocks
Pole/Zero awarded over $66M contract by U.S. Department of Defense »

Pole/Zero, part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Hot Stocks
Pier 1 Imports discontinues FY19 guidance »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INDB

Independent Bank

$89.85

0.65 (0.73%)

, BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Hot Stocks
Independent Bank, Blue Hills sign merger pact for Rockland to acquire BHB »

Independent Bank Corp.…

INDB

Independent Bank

$89.85

0.65 (0.73%)

BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Earnings
Pier 1 Imports reports preliminary Q2 EPS (64c)-(62c), consensus (55c) »

Reports Q2 prelim SSS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOD

Gladstone

$19.01

0.28 (1.49%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Hot Stocks
Gladstone acquires $8.3M property in Delaware, Ohio »

Gladstone Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$46.03

0.98 (2.18%)

16:15
09/20/18
09/20
16:15
09/20/18
16:15
Hot Stocks
Micron appoints Mike Bokan SVP Worldwide Sales »

Micron Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

16:15
09/20/18
09/20
16:15
09/20/18
16:15
General news
Breaking General news story  »

Week of 9/10 Money Supply…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.